Data di Pubblicazione:
2023
Citazione:
Use of Oral Anticoagulant Drugs in Patients with Pulmonary Hypertension / P. Demelo-Rodriguez, F. Galeano-Valle, M. Proietti. - In: HEART FAILURE CLINICS. - ISSN 1551-7136. - 19:1(2023 Jan), pp. 97-106. [10.1016/j.hfc.2022.08.018]
Abstract:
Pulmonary hypertension (PH), in particular pulmonary arterial hypertension and chronic thromboembolic PH, burdens patients with relevant morbidity and mortality. The use of oral anticoagulants (OACs) seems able to mitigate the risk of adverse outcomes and death in these patients. Despite scarce evidence, the use of OAC is recommended to treat PH patients, mainly based on observational data. So far, data are still unclear about the impact of direct oral anticoagulant (DOACs), whereas vitamin K antagonists are the main drugs recommended. More data are needed to fully clarify the role of OAC and DOACs in PH patients.
Tipologia IRIS:
01 - Articolo su periodico
Keywords:
DOACs; Oral anticoagulant drugs; Pulmonary hypertension; VKAs;
Elenco autori:
P. Demelo-Rodriguez, F. Galeano-Valle, M. Proietti
Link alla scheda completa: